资讯与洞察

DOT 5 Panel Notice Posted on the ODAPC Site

The following is from:
https://www.transportation.gov/odapc/DOT_5_Panel_Notice_2018

DOT Drug Testing: After January 1, 2018 – Still a 5-Panel

The DOT testing at HHS-certified laboratories is a 5-panel drug test regimen. As of January 1, 2018, the ‘Opiates’ category was renamed ‘Opioids’:

  • Marijuana (THC)
  • Cocaine
  • Amphetamines
  • Opioids
  • Phencyclidine (PCP)

Under ‘Opioids’, previously ‘Opiates’, DOT testing will continue to include confirmatory testing, when appropriate, for Codeine, Morphine, and 6-AM (heroin). We added initial and confirmatory testing for the semi-synthetic opioids Hydrocodone, Hydromorphone, Oxycodone, and Oxymorphone to this Opioids group. Some brand names for the semi-synthetic opioids include OxyContin®, Percodan®, Percocet®, Vicodin®, Lortab®, Norco®, Dilaudid®, Exalgo®.

Under Amphetamines, DOT testing includes confirmatory testing, when appropriate, for Amphetamine, Methamphetamine, MDMA, and MDA. To this Amphetamines group, we added initial testing for MDA and removed testing for MDEA.

Since January 1st, we have required confirmation testing for 14 drugs under a 5‑panel test. Broken out, here is what DOT drug testing looks like:

  • Marijuana (THC)
  • Cocaine
  • Amphetamines
  • Amphetamine
  • Methamphetamine
  • MDMA
  • MDA
  • Opioids
  • Codeine
  • Morphine
  • 6-AM (heroin)
  • Hydrocodone
  • Hydromorphone
  • Oxycodone
  • Oxymorphone
  • Phencyclidine (PCP)

For DOT testing, what does this mean for collectors, laboratories, MROs, and employers after January 1st ,2018?

Collectors will continue to check the 5-panel box in Step 1 of the CCF: That is, the box specified for “THC, COC, PCP, OPI, AMP.”

Laboratories will:

  • continue to report to MROs the specific drugs / drug metabolites they confirm as positive, and laboratories will add hydrocodone, hydromorphone, oxycodone, and oxymorphone confirmed positives, as appropriate.
  • on their semi-annual reports to DOT and their semi-annual reports to employers add: hydrocodone; hydromorphone; oxycodone; and oxymorphone confirmed positive totals, as appropriate, under Opioids.

MROs will continue to report to employers the specific drugs / drug metabolite they verify as positive; and MROs will add hydrocodone, hydromorphone, oxycodone, and oxymorphone verified positives, as appropriate.

Employers will continue to provide – on their annual MIS reports – the number of verified positive drug test results in each testing category (i.e., Marijuana, Cocaine, Amphetamines, Opioids, and PCP).

Updated: Tuesday, March 6, 2018

本内容仅供参考。First Advantage(首优咨询有限公司)并非律师事务所,本内容不构成且不代表任何形式的法律意见。本内容所含信息并非最新的法律或其他资讯。

本内容读者应针对个人具体情况咨询其自有法律顾问。任何读者以及使用者均不应基于本内容信息采取行动或不采取行动。唯有您的执业律师或法律顾问能够确保本内容所含信息及您对其之解读适用或适合您的特定情况。使用或查看本内容不会使读者以及使用者与First Advantage(首优咨询有限公司)建立律师-客户关系。

About First Advantage

在整个招聘过程中,全球领先的人力资源团队选择首优咨询完成背景调查、身份验证、安全评估和合规审批。我们一贯力求实现技术与人员之间的平衡,以创新助您智慧招聘,迅捷上岗。

全心全意,以人为本

首优咨询致力于环境、社会和公司治理举措优化,以提升工作环境。

现已发布!

2024年趋势报告揭示行业洞察